Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives. Reck M, Popat S, Grohe C, Corral J, et al. Lung Cancer 2023;179:107173.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Reck M, Popat S, Grohe C, Corral J, et al. Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives. Lung Cancer 2023;179:107173.
PMID: 36940614